CAS 168650-46-2
:(Asp371)-Tirosinasi (369-377) (umano)
- [Asp370]-Tyrosinase (368-376)
- Asp371, Tyrosinase 369-777, Human
- Tyr-Met-Asp-Gly-Thr-Met-Ser-Gln-Val
- Ymdgtmsqv
[Asp371]-Tyrosinase (369-377), human
CAS:Tyrosinase (369-377,YMDGTMSQV) originates from tyrosinase and needs TAP and proteosome for cell presentation.Formula:C42H66N10O16S2Purezza:98%Colore e forma:SolidPeso molecolare:1031.16[Asp371]-Tyrosinase (369-377), human
CAS:Custom research peptide; min purity 95%. For different specs please use the Peptide Quote Tool
Formula:C42H66N10O16S2Peso molecolare:1,031.2 g/mol[Asp371] Tyrosinase(369-377), human
CAS:H-YMDGTMSQVA-OH peptide, corresponding to 369-377 amino acids of enzyme tyrosinase. As a member of the tyrosinase family the corresponding enzyme catalyzes monopheol hydroxylation, dihydroxyindole and catechol dehydrogenation. It is a key enzyme in the conversion of tyrosine to melanin.
Formula:C42H66N10O16S2Purezza:Min. 95%Peso molecolare:1,031.16 g/mol(Asp371)-Tyrosinase (369-377) (human) acetate salt
CAS:Tyrosinase protein:
Peptide Tyrosinase (Asp371) – HLA-A*0201 (YMDGTMSQV) is a human tyrosinase-derived (369-377) peptide by posttranslational conversion of the sequence YMNGTMSQV. Tyrosinase is an oxidase membrane-bound protein. Tyrosinase play a key role in the melanin synthesis pathway. Tyrosinase is presented on the surface of HLA-A*02:01 melanomas and also expressed in melanocytes. Tyrosinase has been still suggested to be a tumor antigen and might be implicated in improvement of immunotherapeutic strategies such as for efficient anticancer vaccine development.
Applications of Peptide Tyrosinase (Asp371) – HLA-A*0201 (YMDGTMSQV):
Peptide Tyrosinase (Asp371) – HLA-A*0201 (YMDGTMSQV) is used to stimulate specific cytotoxic T lymphocytes (CTL) in PBMCs and then to analyze CTL response especially the cytokine production by ELISPOT assay. Peptide Tyrosinase (Asp371) – HLA-A*0201 (YMDGTMSQV) is also involved in experimental therapies of metastatic melanoma by allogeneic hematopoietic stem cell transplantation. In fact, cytotoxic T cells were generated from peripherical blood mononuclear cells (PBMCs) of HLA-A*02:01 healthy donors after being stimulated by injection of Asp371 antigen (2). This strategy raises issues which concern the graft versus tumor (GvT) effect and graft versus host disease (GvHD).Formula:C42H66N10O16S2Purezza:Min. 95%Peso molecolare:1,031.16 g/mol(Asp371)-Tyrosinase (369-377) (human) trifluoroacetate salt
CAS:Trifluoroacetate saltFormula:C42H66N10O16S2Purezza:Min. 95%Peso molecolare:1,031.16 g/molRef: 3D-FA110240
Prodotto fuori produzione

